Fueling the Development of Next-Generation Metabolic Therapeutics
Introducing the iLite® Metabolic Panel for Functional Characterization & Potency Assessment
Metabolic drug development is moving fast, and so are the analytical needs that come with it. As the field advances from single-target approaches towards dual- and triple-agonist therapies, developers need functional data that helps them understand how candidates act across the biological pathways that matter most in obesity, diabetes, and related metabolic diseases.
Today, Svar Life Science launches the iLite® Metabolic Panel, a new suite of assay-ready, cell-based reporter gene assays created to help metabolic drug developers generate biologically relevant functional data faster. The panel supports functional characterization and potency assessment of candidates targeting GLP-1, GIP, FGF-21, and insulin signaling. The assays can be used to evaluate individual targets or in combination to support more complex single-, dual-, and triple-agonist programs involving peptide therapeutics, biologics, and emerging metabolic drug candidates.
The panel is built around key metabolic targets shaping today's drug development landscape and includes:
• NEW iLite® GLP-1 Assay Ready Cells
• NEW iLite® GIP Assay Ready Cells
• iLite® FGF-21 Assay Ready Cells
• iLite® Insulin Assay Ready Cells
The new GLP-1 and GIP reporter gene cell lines complement Svar’s established iLite® assays for FGF-21 and insulin signaling, expanding the iLite cell-based portfolio for researchers working across today’s most relevant metabolic pathways.
Built for the Demands of Next-Generation Metabolic Programs
As therapeutic strategies become more advanced, teams need practical tools that can support decision-making without adding unnecessary assay development burden.
With assay ready cells covering GLP-1, GIP, FGF-21, and insulin signaling, the iLite® Metabolic Panel helps researchers move from complex pathway biology to actionable functional readouts. By translating receptor-mediated pathway activation into quantitative reporter responses, the assays provide functional insight beyond binding measurements alone, helping researchers evaluate biological activity and potency in a relevant cellular context.
The assays are designed to support key development activities, including:
-
Candidate selection and lead optimization
-
Functional characterization
-
Potency assessment
-
Process and method development
-
Method validation and transfer
-
Biosimilar comparability studies
For developers, the value lies in speed, relevance, and flexibility: functional readouts that reflect pathway activation, assay ready models that simplify setup, and a modular panel that can be tailored to the questions being asked in each program. High assay sensitivity and broad dynamic range help support robust quantification of biological responses, enabling confident assessment across a wide range of activity levels.
All iLite assay ready cells are supplied in a thaw-and-use format, reducing the cell preparation and recovery steps typically associated with conventional cell-based assays and enabling iLite assays to be performed in under one day.
- Assays can be performed in under one day
- Thaw-and-use assay-ready cells help reduce preparation time and manual handling
- Streamlined workflow supports efficient candidate screening, potency assessment, and cross-program comparisons
Together, these features help laboratories:
-
Generate biologically relevant functional data earlier in development
-
Assess potency across a broad dynamic range
-
Reduce hands-on preparation with assay ready cells
-
Adapt the panel to single-target, dual-agonist, or triple-agonist programs
-
Make informed development decisions faster
As metabolic innovation expands beyond traditional single-target therapies, researchers need assays that help translate complex biology into data they can act on. The iLite® Metabolic Panel gives development teams a practical way to assess activity across key metabolic pathways and progress promising candidates with greater confidence.
Whether developing a GLP-1 agonist, a dual incretin molecule, or a next-generation metabolic therapeutic, researchers can select and combine assays from the iLite Metabolic Panel to create a testing strategy aligned with their development objectives.
